Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

FDA says Integrilin is approvable

April 3, 1998

Mechanism of vasorelaxant effects of HFV-1017C elucidated

April 2, 1998

Banyu develops factor Xa inhibitors as antiplatelet/antithrombotic agents

April 2, 1998

Preliminary results of TIMI 15A trial reported at ACC

April 1, 1998

Anticoagulants in development at DuPont Merck

April 1, 1998

Potent and selective PDE III inhibitor in development at Otsuka

March 31, 1998

New antiplatelet and antithrombotic agent characterized by Taisho

March 31, 1998

Toyama researchers characterize antiplatelet/antithrombotic effects of T-250

March 31, 1998

Platelet antiaggregatory effects of liposome-encapsulated streptokinase

March 30, 1998

Z-335 demonstrates beneficial effects in models of peripheral circulatory insufficiency

March 30, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.